Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 29;13(3):9262.
doi: 10.4081/dr.2021.9262. eCollection 2021 Nov 17.

Paraneoplastic dermatomyositis and prostate cancer: Myopathy regression under cancer-directed therapy

Mafalda Miranda Baleiras  1 , Luís Maduro  1 , Carolina Vasques  1 , Filipa Ferreira  1 , Marta Mesquita Pinto  1 , Ana Martins  1
Affiliations

Paraneoplastic dermatomyositis and prostate cancer: Myopathy regression under cancer-directed therapy

Mafalda Miranda Baleiras et al. Dermatol Reports. .

Abstract

Prostate cancer is the second most frequent malignancy in men worldwide and the fifth leading cause of death. Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by musculocutaneous manifestations. However, DM can also present as a paraneoplastic syndrome of an underlying neoplasm. We report a case of a 65-year-old man diagnosed with prostate adenocarcinoma in the setting of severe dysphagia, muscle weakness and a facial erythematous rash. At first, the DM-related symptoms resolved with the initial treatment for the underlying malignancy. Yet, they flared up as the tumor progressed. To sum up, DM is a rare systemic disorder with unknown etiology. There is a well-established association between DM and malignancy. Malignancy-headed therapy can improve DM manifestations and the recurrence of DM symptoms may act as an early warning of malignancy relapse.

Keywords: Dermatomyositis; Myositis- Specific Antibody; Paraneoplastic Syndrome; Prostate Cancer; Recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare no potential conflict of interests.

Figures

Figure 1.
Figure 1.
Image A: Oblique axial CT plane shows an enlarged and asymmetric prostate (P) with prominent nodular densities extending posteriorly into the periprostatic space. Transrectal prostate biopsy revealed cancer in this area. Image B: Sagittal CT plane. Image C: different oblique axial CT plane. These latter planes demonstrate the tumor (T) also spreading superiorly, with infiltration of fat between the left seminal vesicle (SV) and the rectum wall (R) and loss of the fat planes between these structures. CT is not accurate to characterize locally the prostatic cancer. MRI is the imaging method for regional staging, but the presence of disseminated disease, shown by non-regional/distant metastatic adenopathies (Adp), made MRI unnecessary.
Figure 2.
Figure 2.
CT images. The right image (Axial CT scan) shows progressive disease with an increase of retroperitoneal lymph nodes, comparing to the CT performed nine months before (left image).
See this image and copyright information in PMC

References

    1. Baijens LW, Manni JJ. Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol 2006;263:32-6. - PubMed
    1. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish populationbased cohort study. Br J Cancer 2001; 85:41-5. - PMC - PubMed
    1. Olazagasti JM, Baez PJ, Wetter DA, Ernste FC. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 2015;16: 89-98. - PubMed
    1. Motomura K, Yamashita H, Yamada S, et al. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. Rheumatol Int 2019;39:1733-9. - PubMed
    1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019;10:63-8. - PMC - PubMed